11 results about "Live vector vaccine" patented technology

The application discloses a novel goose parvovirus VP1 protein truncated body gene, a recombinant duck plague virus and application. The novel goose parvovirus VP1 protein truncated body gene has a nucleotide sequence shown as SEQ ID No. 1. The recombinant duck plague virus has the novel goose parvovirus VP1 protein truncated body gene inserted into the genome of the recombinant duck plague virus. The application obtains a novel goose parvovirus VP1 protein truncated body gene, inserts the truncated body into the genome of the recombinant duck plague virus, and obtains the recombinant duck plague virus, and the rsVP1-Cre immune group shortens the NGPV discharge in the duck body, and the duck body immune rsVP1-Cre is helpful to the NGPV discharge. It is shown that the recombinant duck plague virus with the VP1 protein truncated body gene inserted can be used for preparation of a novel goose parvovirus-duck plague virus double live vector vaccine.

The invention belongs to the technical field of biological medicines, and particularly relates to a lactic acid bacteria live vector vaccine for preventing and treating brucellosis and a preparation method of the lactic acid bacteria live vector vaccine. The lactic acid bacteria live vector vaccine is obtained by transferring expression vectors for expressing Brucella omp19 protein and BvrR protein into lactic acid bacteria, and the lactic acid bacteria are lactobacillus cavings. The lactobacillus live vector vaccine for preventing and treating brucellosis is constructed by taking brucella omp19 protein and BvrR protein as immunogens and lactic acid bacteria as an antigen transfer vector, and the safety is good. After the vaccine is used for immunizing mice, the mice can obtain a higher antibody level, the duration is long, brucella infection is effectively inhibited, meanwhile, the production process of the vaccine is simplified, and the vaccine has a good application prospect.

The application provides a kind of construction and application of PRRSV live vector vaccine strain of recombination expression PEDV S protein receptor RBD domain, and the results show that the dominant antigen region of PEDV S protein RBD function domain can be expressed in the recombination virus rHuN4-F112-SRBD1 rescued, and the biological characteristics of recombination virus are similar to parent virus.The nucleotide sequence of SRBD1 gene introduced in each generation of recombination virus and the amino acid sequence encoded thereby are not deleted or mutated, and the IFA and Western Blot detection results show that the SRBD1 gene introduced in different generations of recombination virus rHuN4-F112-SRBD1 can be stably expressed, and does not affect the expression of parent virus itself protein, indicating that the recombination virus rHuN4-F112-SRBD1 strain has genetic stability.The immunogenicity analysis of recombination virus rHuN4-F112-SRBD1 shows that the recombination virus rHuN4-F112-SRBD1 strain can induce specific antibodies against PEDV S protein and PRRSV2 in piglets after immunization, and the antibodies induced have neutralizing effect on PEDV epidemic strain, and can be used for the development and development of PRRS and PED novel genetic engineering vaccine.

This invention belongs to the field of viral genetic engineering technology and discloses a bovine herpesvirus type 1 (BHV-1) with three gene deletions, its construction method, and its applications. Using a Fosmid library, four myxovirus rescue combinations were screened. FosBHV-1-b-ΔTK-mCherry and FosBHV-1-d-ΔgEct / US9-eGFP were obtained through Red / ET and Gateway methods. These were then combined with FosBHV-1-a and FosBHV-1-c to construct an infectious cloning platform for recombinant BHV-1 with the TK / gEct / US9 three-gene deletions, rescuing recombinant viruses carrying tracer genes. This method has high recombination efficiency, and the cloning platform can efficiently construct BHV-1 gene-deleted strains. The immunogenicity of the deleted strains is comparable to that of wild-type viruses, with good safety, providing an efficient technical means for the development of BHV-1 attenuated vaccines and bovine disease live vector vaccines.

The invention discloses recombinant lactic acid bacteria for preparing a PDCoV oral live vector vaccine as well as a construction method and application of the recombinant lactic acid bacteria, and relates to the technical field of biology. The construction method of the recombinant lactic acid bacteria comprises the following steps: cloning and connecting a coding gene of a PDCoV-S protein to an expression vector, and converting lactobacillus plantarum to prepare the recombinant lactic acid bacteria of which the surface displays the PDCoV-S protein, the amino acid sequence of the PDCoV-S protein is as shown in SEQ ID NO. 2. The recombinant lactic acid bacteria provided by the invention have good tolerance in different environments, are safe and free of toxic effects, can effectively cause systemic immune response and intestinal local mucosa immune response, and have good immunogenicity. The invention provides powerful technical support for developing a PDCoV oral live vector vaccine, and has important significance for preventing and controlling PDCoV infection.

The invention discloses a duck plague virus UL51 gene deletion strain and a construction method and application thereof, the deletion strain is preserved in China Center for Type Culture Collection in Wuhan University in China on April 2, 2025, and the preservation number is CCTCC NO: V202523. The method comprises the following steps: deleting a UL51 gene to obtain an infectious clone pDPV CHv-deltaUL51 of a UL51 gene deleted strain, and transfecting a duck source cell with the infectious clone DNA to obtain the UL51 gene deleted virus strain DPV CHv-deltaUL51. Detecting immune ducklings infected by viruses, and finding that the deletion of the UL51 gene weakens the duplication of DPV in the ducks and reduces the pathogenicity of the ducks; after the immunized duck is attacked by the DPV virulent CHv strain, the DPV virulent CHv strain can be prevented from lethal attack. The virus strain constructed by the invention has reduced pathogenicity to ducks, and has the potential of being used as a universal vector of an attenuated vaccine or a duck live vector vaccine.

The invention provides a preparation method and application of low-pathogenicity avian influenza virus positive serum, and belongs to the technical field of veterinary biological products. The low-pathogenicity avian influenza virus positive serum with high HI titer and neutralizing titer can be obtained by adopting a method of respectively immunizing the live virus and the inactivated vaccine once. The preparation method disclosed by the invention is not limited to the low-pathogenicity avian influenza virus of a single subtype. The positive serum prepared by the method has the characteristics of good specificity, strong sensitivity and the like, and can be used for technical detection of indirect immunofluorescence, western blot, immunohistochemistry and the like; and the kit can also be used for exogenous virus detection of poultry virus live vaccines, separation and identification of clinical viruses, identification and inspection of live vector vaccines, clinical monitoring of avian influenza viruses, epidemiological investigation and immune effect evaluation of related vaccines.

This invention claims protection for a method for constructing and applying a recombinant live vector vaccine capable of simultaneously expressing the classical swine fever virus (CSFV) E2 gene and IL18 gene. After transfecting MARC-145 cells with the chimeric plasmid pPRRSV-E2-N-IL18-Y, live virus was successfully rescued. Furthermore, the recombinant virus rPRRSV-E2-N-IL18-Y was found to have similar virological characteristics to the parental virus vHuN4-F112 and the recombinant virus rPRRSV-E2. In porcine immunization experiments using the recombinant virus rPRRSV-E2-N-IL18-Y, it was found that the recombinant virus exhibited good safety in pigs, effectively inducing an immune response after immunization, producing high levels of antibodies against both the PRRSV N protein and the CSFV E2 protein, and inducing even higher levels of cellular immunity. This makes it a promising candidate strain for a genetically engineered vaccine.

This invention relates to a reverse genetics operating system for the segmented cloning and rescue of the Bartha K61 pseudorabies virus vaccine strain genome, its construction method, and its application. The system includes: recombinant plasmids BAC-cm-PRV-EA, BAC-cm-PRV-BC, and BAC-cm-PRV-FG containing the complete genome of the Bartha K61 pseudorabies virus vaccine strain, and host cells expressing the complete genome of the Bartha K61 pseudorabies virus vaccine strain. The reverse genetics operating system for the Bartha K61 pseudorabies virus vaccine strain of this invention successfully segments the Bartha K61 genome into six segments using ExoCET cloning and assembly technology, and then assembles them into three recombinant plasmids: BAC-cm-PRV-EA, BAC-cm-PRV-BC, and BAC-cm-PRV-FG. These three recombinant plasmids, after PacI linearization, can be co-transfected into African green monkey kidney cells to rescue the Bartha K61 virus, and the infectivity of the rescued Bartha K61 virus is comparable to that of the vaccine strain. Therefore, this reverse genetics operating system can provide an excellent vector for creating live vector vaccines related to the prevention and treatment of swine diseases, and can be used to develop Bartha K61 recombinant genetic engineering vector vaccines that express relevant swine disease antigen genes.

The application belongs to the technical field of biological pharmacy, and discloses a recombinant lactococcus lactis live carrier vaccine, which is obtained by connecting a urease subunit UreA gene with a plasmid expression vector and then electrically transforming the lactococcus lactis; the amino acid sequence of the urease subunit UreA gene is shown as SEQ ID NO. 1. The application further discloses application of the recombinant lactococcus lactis live carrier vaccine in preparation of an anti-helicobacter pylori vaccine. The recombinant lactococcus lactis live carrier vaccine provided by the application can effectively stimulate the body to produce a mucosal immune response and has good protection effect.

The application provides a virus in the preparation of bacteriophage, and belongs to the technical field of bacteriophage. The application provides PCV2, phPCV2, PCV3, phPCV3, HEV or phHEV in the preparation of bacteriophage. The application first proposes that eukaryotic viruses can infect bacteria and can replicate in the bacteria, and the viruses show the characteristics of lysogenic bacteriophage. The application has broad spectrum for the infection of the bacteria, can effectively inhibit the reproduction of the bacteria, and has a pioneering significance for developing broad-spectrum bacteriophage bactericides and developing vaccines by using the infection of the viruses on the bacteria. The application can stably amplify the viruses with high toxicity by using Escherichia coli, and the inactivated vaccines prepared by the viruses can significantly protect animals. The application also prepares a RecA-deficient Bacillus subtilis live vector vaccine, so that the virus infection is stably in a lysogenic state for a long time, and the animals are inoculated by oral administration, the animals are colonized in the intestinal tract, and the antigen is continuously expressed to induce a mucosal immune response.